Provided by Tiger Fintech (Singapore) Pte. Ltd.

Coherus BioSciences

1.03
-0.0200-1.90%
Volume:1.19M
Turnover:1.23M
Market Cap:118.67M
PE:-260.17
High:1.09
Open:1.05
Low:1.01
Close:1.05
Loading ...

BUZZ-Coherus Bio jumps on deal to divest biosimilar of Amgen's Neulasta

Reuters
·
03 Dec 2024

Coherus BioSciences to Divest Udenyca to Intas Pharmaceuticals for Up to $558 Million

MT Newswires Live
·
03 Dec 2024

Coherus BioSciences Shares Rise 22% on Divestiture Agreement With Intas Pharmaceuticals

Dow Jones
·
03 Dec 2024

Coherus Biosciences agrees to divest UDENYCA franchise for up to $558M

TIPRANKS
·
03 Dec 2024

Coherus Announces Agreement to Divest Udenyca® Franchise for up to $558 Million to Intas Pharmaceuticals Ltd.

THOMSON REUTERS
·
03 Dec 2024

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

GlobeNewswire
·
03 Dec 2024

RDY Launches Loqtorzi Biosimilar in India for Nasopharyngeal Carcinoma

Zacks
·
29 Nov 2024

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

GlobeNewswire
·
28 Nov 2024

Coherus Biosciences (CHRS) Receives a Buy from Barclays

TIPRANKS
·
18 Nov 2024

Coherus Biosciences price target lowered to $4 from $8 at Baird

TIPRANKS
·
08 Nov 2024

Coherus stock rallies 19% on Q3 earnings, Udenyca production update

seekingalpha
·
08 Nov 2024

Q3 2024 Coherus BioSciences Inc Earnings Call

Thomson Reuters StreetEvents
·
08 Nov 2024

Reported November 6: Coherus BioSciences Q3 2024 Adj EPS $(0.01) Beats $(0.12) Estimate, Sales $70.77M Beat $59.23M Estimate

Benzinga
·
08 Nov 2024

Coherus BioSciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
07 Nov 2024

Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...

GuruFocus.com
·
07 Nov 2024

Coherus BioSciences Reports Strong Q3 2024 Growth

TIPRANKS
·
07 Nov 2024